Table I.
Patient demographics across RAP/PCWP ratio quartiles (n = 367)
| Q1 (<0.43) | Q2 (0.43-0.58) | Q3 (0.58-0.75) | Q4 (≥0.75) | P | |
|---|---|---|---|---|---|
| Age (y) | 58 ± 10 | 56 ± 14 | 58 ± 14 | 57 ± 12 | .65 |
| Male | 84.8% | 78.0% | 72.8% | 64.8% | .001* |
| ICM | 46.7% | 49.5% | 52.2% | 37.0% | .18 |
| LVEF(%) | 17 ± 8 | 17±7 | 19±10 | 27 ± 18 | <.0001 |
| LVEDD (cm) | 6.6 ± 1.1 | 6.6 ±1.1 | 6.3 ± 1.2 | 6.0 ± 1.4 | .02 |
| Diabetes mellitus II | 31.5% | 37.4% | 41.3% | 43.5% | .08* |
| ICD | 58.7% | 47.3% | 48.9% | 43.6% | .06* |
| CRT | 25.0% | 24.4% | 26.1% | 27.5% | .97 |
| β-Blocker | 74.7% | 60.0% | 78.6% | 65.2% | .03 |
| ACEI | 67.1% | 52.6% | 52.6% | 38.8% | .001* |
| ARB | 13.4% | 17.1% | 14.1% | 16.4% | .90 |
| Digoxin | 57.1% | 41.8% | 41.3% | 40.2% | .03 |
| Loop diuretic | 97.8% | 87.9% | 90.2% | 91.2% | .05 |
| Vasodilator (ICU) | 80.0% | 80.0% | 73.9% | 48.9% | .006 |
| Inotrope (ICU) | 59.8% | 48.4% | 45.7% | 59.3% | .11 |
| Loop diuretic (ICU) | 68.6% | 62.9% | 78.3% | 56.8% | .16 |
Continuous variables are expressed as mean ± SD or median (IQR). Missing values: LVEF and LVEDD: 102. Abbreviations: ICM, Ischemic cardiomyopathy; ICD, implanted cardiac defibrillator; CRT, cardiac resynchronization therapy; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.
*
P value determined by Cochran-Armitage trend test; other P values for continuous parametric variables calculated via ANOVA, for continuous nonparametric via Kruskal-Wallis test, and for categorical variables by χ2 method.